Alumis' Envudeucitinib Shows Leading Phase 3 Psoriasis Efficacy; $345M Offering Funds NDA Path
summarizeSummary
Alumis Inc. announced highly positive Phase 3 topline results for its lead candidate, envudeucitinib, in moderate-to-severe plaque psoriasis, demonstrating leading skin clearance (65% PASI 90, 40% PASI 100) and a favorable safety profile. This strong data supports the company's plan to submit a New Drug Application (NDA) for envudeucitinib in psoriasis in the second half of 2026. Concurrently, Alumis successfully completed an upsized public offering in January 2026, raising approximately $345.1 million in gross proceeds, significantly bolstering its cash position to fund ongoing development and regulatory efforts. The company also highlighted anticipated pivotal Phase 2b clinical topline data for envudeucitinib in systemic lupus erythematosus (SLE) in Q3 2026, which could further expand the drug's potential. These developments collectively de-risk the company's lead asset and provide substantial financial runway, making this a critical update for investors. Traders should monitor the upcoming NDA submission and SLE trial results as key catalysts.
At the time of this announcement, ALMS was trading at $25.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $2.76 to $30.60. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.